Histone deacetylase‐mediated silencing of PSTPIP2 expression contributes to aristolochic acid nephropathy‐induced PANoptosis

Abstract

Background and PurposeAristolochic acid nephropathy (AAN) is a progressive kidney disease caused by using herbal medicines. Currently, no therapies are available to treat or prevent AAN. Histone deacetylase (HDAC) plays a crucial role in the development and progression of renal disease. We tested whether HDAC inhibitors could prevent AAN and determined the underlying mechanism.Experimental ApproachHDACs expression in the aristolochic acid nephropathy model was examined. The activation of PANoptosis of mouse kidney and renal tubular epithelial cell were assessed after exposure to HDAC1 and HDAC2 blockade. Kidney‐specific knock‐in of Proline‐serine‐threonine‐phosphatase‐interacting protein 2 (PSTPIP2) mice were used to investigate whether PSTPIP2 affected the production of PANoptosome.Key ResultsAristolochic acid upregulated the expression of HDAC1 and HDAC2 in the kidneys. Notably, the HDAC1 and ‐2 specific inhibitor, romidepsin (FK‐228, Depsipeptide), suppressed aristolochic acid‐induced kidney injury, epithelial cell pyroptosis, apoptosis, and necroptosis (PANoptosis). Moreover, romidepsin upregulated PSTPIP2 in renal tubular epithelial cells, which was enhanced by aristolochic acid treatment. Conditional knock‐in of PSTPIP2 in the kidney protected against AAN. In contrast, the knockdown of PSTPIP2 expression in PSTPIP2‐knockin mice restored kidney damage and PANoptosis. PSTPIP2 function was determined in vitro using PSTPIP2 knockdown or overexpression in mTECs. Additionally, PSTPIP2 was found to regulate Caspase‐8 in Aristolochic acid nephropathy.Conclusion and ImplicationsHDAC‐mediated silencing of PSTPIP2 may contribute to aristolochic acid nephropathy. Hence, HDAC1 and ‐2 specific inhibitors or PSTPIP2 could be valuable therapeutic agents for preventing aristolochic acid nephropathy.